References
- Polenakovic M, Stefanovic V. Balkan nephropathy. In: Cameron J. S., Davison A. M., Grunfeld J. P., Kerr D., Ritz E., editors. Oxford Textbook of Clinical Nephrology. 1st. Oxford, UK: Oxford University Press; 1992. pp. 857–866.
- Djukanović L, Radovanović Z. Balkan endemic nephropathy. In: De Broe M. E., Porter G. A., Bennett W. M., Verpooten G. A., editors. Clinical Nephrotoxins. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2003. pp. 587–601.
- Stefanovic V, Radovanovic Z. Balkan endemic nephropathy and associated urothelial cancer. Nature Clinical Practice Urology. 2008;5(2):105–112.
- Stefanovic V. Current status and research beyond year 2010 in Balkan endemic nephropathy. BANTAO Journal. 2009;7(2):4–9.
- Stefanovic V, Polenakovic M, Toncheva D. Urothelial carcinoma associated with Balkan endemic nephropathy. A worldwide disease. Pathologie Biologie. 2011;59(5):286–291.
- Polenakovic M, Stefanović V. What do we know about the Balkan endemic nephropathy and the uroepithelial tumors? Prilozi. 2014;35(1):11–15.
- Velickovic L. J, Hattori T, Stefanovic V. Molecular markers in upper urothelial carcinoma associated to Balkan endemic nephropathy. Aristolochic acid as the major risk factor of the worldwide disease. The-ScientificWorldJournal. 2009;9: 1360–1373.
- Toncheva D, Dimitrov T, Stojanova S. Etiology of Balkan endemic nephropathy: a multifactorial disease? European Journal of Epidemiology. 1998;14(4):389–394.
- Ivic M. The problem of etiology of endemic nephropathy. Lijecnicki Vjesnik. 1969;91: 1278–1281.
- De Broe M. E. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney International. 2012;81(6):513–515.
- Vanherweghem J.-. Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. The Lancet. 1993;341(8842):387–391.
- Nortier J. L, Martinez M.-C. M, Schmeiser H. H, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fang chi) The New England Journal of Medicine. 2000;342(23):1686–1692.
- Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem J.-L. Identification of aristolochic acid in Chinese herbs. The Lancet. 1994;343(8890):p. 174.
- Yang C.-S, Lin C.-H, Chang S.-H, Hsu H.-C. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. American Journal of Kidney Diseases. 2000;35(2):313–318.
- Chang C.-H, Wang Y.-M, Yang A.-H, Chiang S.-S. Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. American Journal of Nephrology. 2001;21(6):441–448.
- Lord G. M, Cook T, Arlt V. M, Schmeiser H. H, Williams G, Pusey C. D. Urothelial malignant disease and Chinese herbal nephropathy. The Lancet. 2001;358(9292):1515–1516.
- Li X.-B, Xing N.-Z, Wang Y, Hu X.-P, Yin H, Zhang X.-D. Transitional cell carcinoma in renal transplant recipients: a single center experience. International Journal of Urology. 2008;15(1):53–57.
- Cosyns J, Jadoul M, Squifflet J.-P, Van Cangh P, van Ypersele de Strihou C. Urothelial malignancy innephropathy due to Chinese herbs. Lancet 1994, 344, 188.
- Nortier J.L, Martinez Muniz M.-C, Schmeiser H.H, Arlt V.M, Bieler C.A, Petein, M, Depierreux, M.F, de Pauw L, Abramowicz D, Vereerstraeten P, et al. Urothelial carcinoma associated with the use of a Chinese herb. N. Engl. J. Med. 2000, 342, 1686–1692.
- World Health Organization. Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; IARC Press: Lyon, France, 2002; Volume 82.
- Debelle F.D, Vanherweghem J.-L, and Nortier J.L. Aristolochic acid nephropathy: A worldwide problem. Kidney Int. 2008, 74, 158–169.
- Chen C.-H, Dickman K.G, Moriya M, Zavadil J, Sidorenko V.S, Edwards K.L, Gnatenko D.V, Wu L, Turesky R.J, Wu X.-R, et al. Aristolochic acidassociated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. USA 2012, 109, 8241–8246.
- Schmeiser H.H, Janssen J.W.G, Lyons J, Scherf H.R, Pfau W, Buchmann A, Bartram C.R, Wiessler M. Aristolochic Acid Activates ras Genes in Rat Tumors at Deoxyadenosine Residues. Cancer Res. 1990, 50, 5464–5469.
- Lord G.M, Hollstein M, Arlt V.M, Roufosse C, Pusey C.D, Cook T, Schmeiser H.H. DNA adducts and p53 mutations in a patient with aristolochic acidassociated nephropathy. Am. J. Kidney Dis. 2004, 43,e18.1–e18.7.
- Hollstein M, Moriya M, Grollman A.P, Olivier M. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental caecinogen Hollstein M, Moriya M, Grollman A.P, Olivier
- Arlt V.M, Stiborova M, Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis 2002, 17, 265–277
- Slade N, Moll U.M, Brdar B, Zori´c A, Jelakovi´c B. p53 mutations as fingerprints for aristolochic acid— An environmental carcinogen in endemic (Balkan) nephropathy. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2009,663, 1–6.
- Hoang M.L, Chen C.-H, Sidorenko V.S, He J, Dickman K.G, Yun B.H, Moriya M, Niknafs N, Douville C, Karchin R, et al. Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole Exome sequencing.Sci.Trans.Med.2013,5.
- Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovi´c B, Wu L,Truong S, Fernandes A, Grollman A.P. TP53 Mutational signature for aristolochic acid: An environmental carcinogen. Int. J. Cancer 2011, 129, 1532–1536.
- Aydin S, Dekairelle A.-F, Ambroise J, Durant J.-F, Heusterspreute M, Cosyns Y.G.J.-P, Gala J.-L. Unambiguous Detection of Multiple TP53 Gene Mutations in AAN-Associated Urothelial Cancer in Belgium Using Laser Capture Microdissection. PLoS ONE 2014, 9, e106301.
- Wang Y, Meng F, Arlt VM, Mei N, Chen T, Parsons BL. Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and KRas mutant fraction. Mutagenesis. 2011;26: 619–628.
- Olivier M, Hollstein M, Schmeiser HH, Straif K, Wild CP. Upper urinary tract urothelial cancer: where it is A: T. Nat Rev. 2012;12: 503–504.
- Poon SL, Pang ST, McPherson JR, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 2013;5: 197ra101.
- Simmons D. Epigenetic influence and disease. Nature Education. 2008;1(1, article 6)
- Staneva R, Rukova B, Hadjidekova S, et al. Whole genome methylation array analysis reveals new aspects in Balkan endemic nephropathy etiology. BMC Nephrology. 2013;14, article 225
- Kocic G, Cukuranovic J, Stoimenov T. J., et al. Global and specific histone acetylation pattern in patients with Balkan endemic nephropathy, a worldwide disease. Renal Failure. 2014;36(7):1078–1082.
- Neely L. A., Rieger-Christ K. M., Neto B. S., et al. A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urologic Oncology: Seminars and Original Investigations. 2010;2 8(1):39–48.
- Wang G, Zhang H, He H, et al. Up-regulation of microRNA in bladder tumor tissue is not common. International Urology and Nephrology. 2010;42(1):95–102.
- Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–858.
- Bartel D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
- Alvarez-Garcia I, Miska E. A. MicroRNA functions in animal development and human disease. Development. 2005;132(21):4653–4662.
- Calin G. A, Sevignani C, Dumitru C. D, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(9):2999–3004.
- Nikolova D, Toncheva D. RNA interferenceregulations and application in oncology. Journal of Cancer Molecules. 2008;4(3):67–77.
- Kent O. A, Mendell J. T. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46):6188–6196.
- Gottardo F, Liu C. G, Ferracin M, et al. MicroRNA profiling in kidney and bladder cancers. Urologic Oncology: Seminars and Original Investigations. 2007;25(5):387–392.
- Lu J, Getz G, Miska E. A, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
- Stenvang J, Silahtaroglu A. N, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNAbased cancer diagnostics and therapeutics. Seminars in Cancer Biology. 2008;18(2):89–102.
- Tao L, Zeng Y, Wang J, et al. Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. Molecular Medicine Reports. 2015;12(5):6533–6546.
- Meng F, Li Z, Yan J, et al. Tissue-specific microRNA responses in rats treated with mutagenic and carcinogenic doses of aristolochic acid. Mutagenesis. 2014;29(5):357–365.
- Wang Y.-Y, Li Z, Chen T, Zhao X.-M. Understanding the aristolochic acid toxicities in rat kidneys with regulatory networks. IET Systems Biology. 2015;9(4):141–146.
- Popovska-Jankovic K, Noveski P, JankovicVelickovic Lj, Stojnev S, Cukuranovic R, Stefanovic V, Toncheva D, Staneva R, Polenakovic M, PlaseskaKaranfilska D. MicroRNA Profiling in Patients with Upper Tract Urothelial Carcinoma Associated with Balkan Endemic Nephropathy. Biomed Res Int. 2016: 7450461.
- Wei S, Yao Y, Gupta P. K, Bing Z. miRNA expression in lower and upper urothelial carcinoma and the potential clinical application. Proceedings of the 102nd United States and Canadian Academy of Pathology Annual Meeting (USCAP ‘13); March 2013; Baltimore, Md, USA. Baltimore Convention Center.
- Blick C, Ramachandran A, Wigfield S, McCormick R, Jubb A, Buffa FM, et al. Hypoxia regulates FGFR3 expression via HIF-1alpha and miR100 and contributes to cell survival in non-muscle invasive bladder cancer. Br J Cancer. 2013; 109 (1):509.
- Ratert N, Meyer HA, Jung M, Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, Jung K. Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One. 2012; 7:e39309.
- Wu C.F, Pang S.T, Shee J.J, Chang P.L, Chuang C.K, Chen C.S, Liao S.K, Weng W.H. Identification of genetic alterations in upper urinary tract urothelial carcinoma in end-stage renal disease patients. Genes Chromosomes Cancer 2010, 49, 928–934.
- Kurataka O and Takahiro O. Genetic Networks Lead and Follow Tumor Development: MicroRNA Regulation of Cell Cycle and Apoptosis in the p53 Pathways. Biomed Res Int. 2014; 2014: 749724.
- Munekazu Yamakuchi. MicroRNA Regulation of SIRT1. Front Physiol. 2012; 3: 68.
- Pramanik D, Campbell N. R, Karikari C, Chivukula R, Kent O. A, Mendell J. T, Maitra A. Restitution of tumor suppressor microRNAs using a systemic nano vector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 2011; 10, 1470–1480.
- Pogribny I P, Muskhelishvili L, Tryndyak V. P, Beland F. A. The tumor-promoting activity of 2acetylaminofluorene is associated with disruption of the p53 signaling pathway and the balance between apoptosis and cell proliferation. Toxicol. Appl. Pharmacol. 2009; 235, 305–311.
- Yunshu Y,Yang L, Yunwei W, Yongyi Ch, Jinxin Zh, Yanhui J, Jun T, Dahai H. Regulation of SIRT1 and Its Roles in Inflammation. Front Immunol. 2022; 13: 831168.
- Ivic N. The problem of etiology of endemic nephropathy. Lijecnicki Vjesnik. 1969; 91: 1278–1281.
- Pavlović Nikola. Balkan endemic nephropathy—current status and future perspectives. Clinical Kidney Journal. 2013; 257–26.
- Jadot I,Declèves A, Nortier J, Caron N. An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature. Int. J. Mol. Sci. 2017; 18(2), 297.